5-nitro-2-vinylfuran | 71258-91-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 5-nitro-2-vinylfuran
• 英文别名: Furan, 2-ethenyl-5-nitro-；2-ethenyl-5-nitrofuran
• CAS: 71258-91-8
• 化学式: C₆H₅NO₃
• 分子量: 139.111
• InChiKey: LDDUFMLKAQVAAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-nitro-2-vinylfuran 在 四氯化碳 、 溴 作用下， 生成 1,2-dibromo-1-(5-nitro-2-furyl)ethane
  参考文献：
  名称：

  Nitrostyrenes and 2-Nitro-5-vinylfuran¹

  摘要：

  DOI：

  10.1021/ja01167a115
• 作为产物：
  描述：

  5-硝基呋喃-2-丙烯酸 生成 5-nitro-2-vinylfuran
  参考文献：
  名称：

  Reaction of ethyl diazoacetate with 2-alkenylfurans

  摘要：

  DOI：

  10.1007/bf00949628

文献信息

• TRIAZOLOPYRIDAZINES AS KINASE MODULATORS
  申请人：Lu Tianbao

  公开号：US20090098181A1

  公开（公告）日：2009-04-16

  The invention is directed to triazolopyridazine compounds of Formula I: where R 1 , R 5 , R 6 , R 7 , R 8 , and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的三唑并吡嗪化合物：其中R1、R5、R6、R7、R8和A如本文所定义，使用这种化合物作为蛋白酪氨酸激酶调节剂，特别是c-Met的抑制剂，并使用这种化合物来减少或抑制细胞或受体中c-Met的激酶活性，调节细胞或受体中c-Met的表达，并使用这种化合物预防或治疗细胞增殖性疾病和/或与c-Met相关的疾病。本发明还涉及包含本发明化合物的制药组合物以及治疗癌症和其他细胞增殖性疾病的方法。
• DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT
  申请人：THURIEAU Christophe

  公开号：US20110059971A1

  公开（公告）日：2011-03-10

  A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R 1 , R 2 and R 3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.

  本申请的主题是公式中R1、R2和R3代表不同基团的新型4-氨基哌啶衍生物及其在液态和固态平行合成方法中的制备过程。这些产物与某些生长抑素受体的亚型具有良好的亲和力，特别适用于治疗某些病理状态或疾病，其中涉及一个（或多个）生长抑素受体。
• Liquid crystal display device comprising improved alignment layers for liquid crystal
  申请人：MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD.

  公开号：EP0351718A1

  公开（公告）日：1990-01-24

  A liquid crystal display device is provided which comprises a cell (c) unit having a pair of optically transparent substrates (1,1') each having an optically transparent electrode layer (2,2') and an alignment layer (3,3') for liquid crystal (7) formed in this order on one side of the substrate (1,1'). The paired substrates (1,1') is in spaced relation with each other and is arranged such that the respective alignment layers (3,3') are facing each other. A liquid crystal (7) is contained in the space between the paired substrates (1,1'). The alignment layers (3,3') are made of a polymer material having both a ring structure and a substituted group at side chains thereof and are subjected to rubbing treatment. The use of the alignment layers (3,3') ensures a great pretilt angle for liquid crystal molecules.

  本发明提供了一种液晶显示装置，它包括一个单元（c）装置，该单元具有一对光学透明基板（1,1'），每个基板（1,1'）都有一个光学透明电极层（2,2'）和一个液晶对准层（3,3'），液晶对准层（3,3'）依次形成在基板（1,1'）的一侧。成对的基板（1,1'）相互间隔排列，并使各自的对准层（3,3'）面对面。液晶 (7) 位于成对基板 (1,1') 之间的空间中。排列层（3,3'）由高分子材料制成，这种材料既具有环状结构，又在其侧链上具有取代基团，并且经过摩擦处理。对位层（3,3'）的使用可确保液晶分子具有较大的前倾角。
• CONDENSED HETEROARYL DERIVATIVES
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1277738A1

  公开（公告）日：2003-01-22

  The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.

  本发明提供了一种可用作磷脂酰肌醇 3 激酶（PI3K）抑制剂和抗肿瘤剂的药物组合物，并提供了一种新型双环或三环融合杂芳基衍生物或其盐，该衍生物具有优异的 PI3K 抑制活性和癌细胞生长抑制活性。
• Vasopressin v1a antagonists
  申请人：Vantia Limited

  公开号：EP2264037A1

  公开（公告）日：2010-12-22

  The present invention relates to compounds with vasopressin V1a antagonist activity and to pharmaceutical compositions comprising such compounds. The present invention also relates to the use of vasopressin V1a antagonists for the treatment of certain physiological disorders, such as Raynaud's disease and dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea).

  本发明涉及具有血管加压素 V1a 拮抗剂活性的化合物以及包含此类化合物的药物组合物。本发明还涉及使用血管加压素 V1a 拮抗剂治疗某些生理疾病，如雷诺氏病和痛经（原发性痛经和/或继发性痛经）。